Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 301–400 of 1,010
Chandra, P., Ali, Z., Fatima, N., Sharma, H., Sachan, N., Sharma, K. K., & Verma, A. K. (2024) · Current Bioactive Compounds · doi:10.2174/0115734072292339240416095600 · Cited by 41
A Multisystemic Approach Revealed Aminated Polystyrene Nanoparticles‐Induced Neurotoxicity
Schröter, L., Jentsch, L., Maglioni, S., Muñoz‐Juan, A., Wahle, T., Limke, A., von Mikecz, A. H., Laromaine, A., & Ventura, N. (2023) · Small · doi:10.1002/smll.202302907 · Cited by 39
The link between Alzheimer’s disease and stroke: A detrimental synergism
Behl, T., Kaur, I., Sehgal, A., Khandige, P. S., Imran, M., Gulati, M., Anwer, M. K., Elossaily, G. M., Ali, N., Wal, P., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102388 · Cited by 38
Hatami, M., Yaghmaee, F., & Ebrahimpour, R. (2024) · Neurocomputing · doi:10.1016/j.neucom.2024.128119 · Cited by 39
Sighencea, M. G., Popescu, R. Ș., & Trifu, S. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212311 · Cited by 38
Lecordier, S., Pons, V., Rivest, S., & ElAli, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.813536 · Cited by 37
Li, Y., Han, X., Fan, H., Sun, J., Ni, M., Zhang, L., Fang, F., Zhang, W., & Ma, P. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136531 · Cited by 34
The Monkey Head Mushroom and Memory Enhancement in Alzheimer’s Disease
Yanshree, Yu, W. S., Fung, M., Lee, C. W., Lim, L. W., & Wong, K.-H. (2022) · Cells · doi:10.3390/cells11152284 · Cited by 38
Karaman, B. K., Mormino, E. C., Sabuncu, M. R., & Initiative, A. D. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277322 · Cited by 43
Bakrim, S., Aboulaghras, S., Menyiy, N. E., Omari, N. E., Assaggaf, H. M., Lee, L., Montesano, D., Gallo, M., Zengin, G., Al-Dhaheri, Y., et al. (2022) · Molecules · doi:10.3390/molecules27249043 · Cited by 38
Bhanukiran, K., Gajendra, T. A., Krishnamurthy, S., Singh, S. K., & Hemalatha, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115145 · Cited by 34
The Application of Artificial Intelligence in Alzheimer's Research
Zhao, Q., Xu, H., Li, J., Akhtar, F., & Qiao, L. (2023) · Tsinghua Science & Technology · doi:10.26599/tst.2023.9010037 · Cited by 42
An eXplainability Artificial Intelligence approach to brain connectivity in Alzheimer's disease
Amoroso, N., Quarto, S., Rocca, M. L., Tangaro, S., Monaco, A., & Bellotti, R. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1238065 · Cited by 40
Novel Para-Aminobenzoic Acid Analogs and Their Potential Therapeutic Applications
Haroon, F., Farwa, U., Arif, M., Raza, M. A., Sandhu, Z. A., Oirdi, M. E., Farhan, M., & Alhasawi, M. A. I. (2023) · Biomedicines · doi:10.3390/biomedicines11102686 · Cited by 36
“…cognitive function, acetylcholine (ACh) is an important neurotransmitter, so enhancing acetylcholine levels at synapses is the primary treat-ment [22]. cholinester-ase Recently, PABA has been featured as an important inhibitor of cholinesterase [23]. acetylcholinesterase Several p -aminobenzoic…”
BackgroundTobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 38
“There are four clinical AD stages (De-Paula et al., 2012; Breijyeh and Karaman, 2020).”
BackgroundInfluentialAtlante, A., & Valenti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115951 · Cited by 35
“There is presently no cure for AD and treatment is limited to symptom management [253,254].”
BackgroundWeaver, D. F. (2023) · Brain Sciences · doi:10.3390/brainsci14010041 · Cited by 39
“…when formulating a mechanistic understanding with which to facilitate management strategies for AD is its immense complexity—a complexity that traverses the full structural and phenomenological spectrum, including molecular, macromolecular, cellular, behavioural and neurological processes [1,2].”
BackgroundNeuroinflammation: A Critical Factor in Neurodegenerative Disorders
Khoury, Z. S., Sohail, F., Wang, J., Mendoza, M., Raake, M., Silat, M. T., Bathinapattla, M. R., Sadeghzadegan, A., Meghana, P., & Paul, J. (2024) · Cureus · doi:10.7759/cureus.62310 · Cited by 44
“The suggested pathways of neuroinflammation will be investigated in this work [38].”
BackgroundSenolytic intervention improves cognition, metabolism, and adiposity in female APPNL−F/NL−F mice
Fang, Y., Peck, M. R., Quinn, K., Chapman, J. E., Medina, D., McFadden, S., Bartke, A., Hascup, E. R., & Hascup, K. N. (2024) · GeroScience · doi:10.1007/s11357-024-01308-8 · Cited by 37
“Currently, AD is considered a multifactorial disease involving tau hyperphosphorylation, Aβ accumulation, inflammation, mitochondrial dysfunction, oxidative stress, and dysregulated cellular communication culminating in neuronal loss [5].”
Application of Nanobiosensor engineering in the diagnosis of neurodegenerative disorders
Dhahi, T. S., Dafhalla, A. K. Y., Al-Mufti, A. W., Elobaid, M. E., Adam, T., & Gopinath, S. C. B. (2024) · Results in Engineering · doi:10.1016/j.rineng.2024.102790 · Cited by 36
Joy, M. A. M., Nasrin, S., Siddiqua, A., & Farid, D. M. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149302 · Cited by 49
Flavonoids and the gut microbiome: a powerful duo for brain health
Taherkhani, S., Ahmadi, P., Nasiraie, L. R., Janzadeh, A., Honardoost, M., & Esfahani, S. S. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2024.2435593 · Cited by 40
“However, it is essential to recognize the crucial role of environmental factors, especially nutrition in brain health (Breijyeh and Karaman 2020; Yao et al. 2004).”
Muhammad, A., Qi, J., Elwasila, O., & Gulzar, Y. (2025) · Brain Sciences · doi:10.3390/brainsci15060612 · Cited by 33
“…images to 224 × 224 pixels to standardize input dimensions, applying a 3 × 3 sharpening filter to enhance structural details such as cortical thinning and hippocampal atrophy [55], and employing contrast limited adaptive histogram equalization (CLAHE) to normalize contrast across scans [56].”
Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Therapeutic Potential of Human Stem Cell Implantation in Alzheimer’s Disease
Chan, H. J., Yanshree, Roy, J., Tipoe, G. L., Fung, M., & Lim, L. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810151 · Cited by 34
Topkara, K. Ç., Kılınç, E., Çetinkaya, A., Şaylan, A., & Demír, Ş. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15565 · Cited by 34
“In addition to aggregated Aβ and phosphorylated Tau, oxidative stress, neuroinflammation and injury to cholinergic neurons also play a key role in the pathophysiology of AD (Breijyeh & Karaman, 2020; Hampel et al., 2018; Moore & O’Banion, 2002; Rangaraju et al., 2018).”
BackgroundDong, Q., Li, Z., Zhang, Q., Hu, Y., Liang, H., & Xiong, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924429 · Cited by 36
“However, clinical trials so far have failed to demonstrate the efficacy of various therapeutics targeting the above mechanisms (Breijyeh and Karaman, 2020).”
BackgroundRasouli, H., Nayeri, F. D., & Khodarahmi, R. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.981984 · Cited by 35
Bonvicini, M., Travaglini, S., Lelli, D., Incalzi, R. A., & Pedone, C. (2023) · Nutrients · doi:10.3390/nu15020386 · Cited by 35
“In the face of this staggering impact on personal and societal health of these conditions, the therapeutic options are somewhat limited [11,20,21], and there is a strong interest in potential strategies for prevention and treatment interventions.”
BackgroundŞenol, H., Turgut, G. Ç., Şen, A., Sağlamtaş, R., Tuncay, S., Gülçın, İ., & Topçu, G. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03031-z · Cited by 34
“Alzheimer’s is a progressive and degenerative disease of the brain characterized by the accumulation of Aβ plaques and neurofibrillary tangles, leading to memory loss and other cognitive problems [49, 50].”
BackgroundMicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer’s Disease
Raffaele, I., Silvestro, S., & Mazzon, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054736 · Cited by 35
“Neuroinflammation seems to play a critical role also in the dysregulation of mitochondrial and synaptic processes, which has been strongly correlated with AD pathogenesis [50,53].”
BackgroundEissa, K. I., Kamel, M. M., Mohamed, L. W., Doghish, A. S., Alnajjar, R. A., Al-Karmalawy, A. A., & Kassab, A. E. (2023) · Drug Development Research · doi:10.1002/ddr.22064 · Cited by 34
Research Progress on Neuroprotective Effects of Isoquinoline Alkaloids
Li, J., Wu, Y., Dong, S., Ye, Y., Wu, Y., Xiang, B., & Qin, L. (2023) · Molecules · doi:10.3390/molecules28124797 · Cited by 35
“The relationship between free radical damage and inflammatory damage is inseparable, and there is a complex interaction between them [102].”
BackgroundDave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 37
“They include donepezil, galantamine, and rivastigmine (AchEI’s) along with memantine (NMDA antagonist) and aducanumab (monoclonal antibody).”
BackgroundInfluentialDing, H., Reiss, A. B., Pinkhasov, A., & Kasselman, L. J. (2022) · Medicina · doi:10.3390/medicina58081025 · Cited by 32
“Furthermore, current medications attack downstream phenomena, like neurotransmitter imbalances, that do not directly address the build-up of beta-amyloid and tau proteins, oxidative stress, or inflammation that are hypothesized to drive AD progression [4,18,21,35] Although there is no cure for Alzheimer’s disease, ind…”
BackgroundMaszka, P., Kwaśniak-Butowska, M., Cysewski, D., Sławek, J. W., Smolenski, R. T., & Tomczyk, M. (2023) · Metabolites · doi:10.3390/metabo13030369 · Cited by 35
“Amino acids Alanine + [87] x - [204] Arginine x - [146] x Asparagine - [88] x - [197] Aspartic acid - [88] - [87] + [194,199] Cysteine + [87] - [87] x Glutamic acid x - [87] x Glutamine + [87] - [87] - [203] Glycine + + [87] x Histidine - [87] x x Homocysteine x + [164] x Isoleucine - [99] + [87] - [43,67] Leucine x x…”
BackgroundZhang, S., Liu, F., Li, J., Jing, C., Lü, J., Chen, X., Wang, D., Cao, D., Zhao, D., & Sun, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115442 · Cited by 33
NFE2L1/Nrf1 serves as a potential therapeutical target for neurodegenerative diseases
Łuczyńska, K., Zhang, Z., Pietras, T., Zhang, Y., & Taniguchi, H. (2023) · Redox Biology · doi:10.1016/j.redox.2023.103003 · Cited by 35
“AD is typically characterized by extracellular A β protein plaques and neurofibrillary tangles composed of the hyperphosphorylated tau protein [77, 78].”
BackgroundSlowing Alzheimer’s disease progression through probiotic supplementation
Medeiros, D., McMurry, K., Pfeiffer, M., Newsome, K., Testerman, T., Graf, J., Silver, A. C., & Sacchetti, P. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1309075 · Cited by 32
Cannabidiol and neurodegeneration: From molecular mechanisms to clinical benefits
Jha, S. K., Nelson, V. K., Suryadevara, P. R., Panda, S. P., Pullaiah, C. P., Nuli, M. V., Kamal, M., Imran, M., Ausali, S., Abomughaid, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102386 · Cited by 35
Harnessing the potential of mesenchymal stem cells–derived exosomes in degenerative diseases
Liao, H., Yang, Y., Liu, Y., Tseng, H., Huo, T., Chiou, S., & Chang, C.-H. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.08.001 · Cited by 34
“AD is characterized by the accumulation of amyloid-beta plaques and neuro fi brillary tangles, leading to a progressive decline in neurological function [107].”
BackgroundRaza, H. A., Ansari, S. U., Javed, K., Hanif, M. I., Qaisar, S. M., Haider, U., Pławiak, P., & Maab, I. (2024) · Scientific Reports · doi:10.1038/s41598-024-81563-z · Cited by 34
Chronic RNA G-quadruplex accumulation in aging and Alzheimer’s disease
Kallweit, L. M., Hamlett, E. D., Saternos, H., Gilmore, A., Granholm, A., & Horowitz, S. A. (2025) · eLife · doi:10.7554/elife.105446.3 · Cited by 37
Sugandhi, V. V., Gadhave, D. G., Ugale, A. R., Kulkarni, N. N., Nangare, S., Patil, H. P., Rath, S., Saxena, R., Lavate, A., Patel, A. T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102775 · Cited by 35
“The physiological mechanisms of AD are greatly influenced by hereditary factors, which are thought to be responsible for between 58 % and 79 % of incidents (Breijyeh and Karaman, 2020; Xiao et al., 2021).”
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 37
“During the Alzheimer’s dementia phase, the individual experiences degenerative impairment in memory and language properties, and behavioral problems progressively increase their impact on the patient’s daily life [3,5,12].”
Cardillo, M., Katam, K., & Suravajhala, P. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1591796 · Cited by 39
Pyroptosis in neurodegenerative diseases: from bench to bedside
Wu, K., Wang, W.-R., Cheng, Q.-H., Li, H., Yan, W.-Z., Zhou, F.-R., & Zhang, R. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09820-x · Cited by 33
Role of TET1-mediated epigenetic modulation in Alzheimer's disease
Armstrong, M. J., Jin, Y., Vattathil, S., Huang, Y., Schroeder, J. P., Bennet, D. A., Qin, Z. S., Wingo, T. S., & Jin, P. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106257 · Cited by 35
“The progression of AD is characterized by an increase in the formation of synaptotoxic A β plaques and neurofibrillary tangles (NFTs), causing synaptic dysfunction, and ultimately synaptic loss (Breijyeh and Karaman, 2020; Knopman et al., 2021).”
Aβ1-42 promotes microglial activation and apoptosis in the progression of AD by binding to TLR4
Dou, R.-X., Zhang, Y., Hu, X., Gao, F.-L., Zhang, L., Liang, Y.-H., Zhang, Y.-Y., Yao, Y.-P., Li, Y., Zhang, Y., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103428 · Cited by 38
“They are also expensive [4].”
Advances in Modeling Alzheimer's Disease In Vitro
Sharma, N. S., Karan, A., Lee, D.-H., Yan, Z., & Xie, J. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100097 · Cited by 34
Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease
Myers, P. S., O'Donnell, J. L., Jackson, J. J., Lessov-Schlaggar, C. N., Miller, R. L., Foster, E. R., Cruchaga, C., Benítez, B. A., Kotzbauer, P. T., Perlmutter, J. S., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200344 · Cited by 35
Kang, N., Luan, Y., Jiang, Y., Cheng, W., Liu, Y., Su, Z., Liu, Y., & Tan, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878631 · Cited by 33
Alzheimer’s disease: The role of T lymphocytes in neuroinflammation and neurodegeneration
Asamu, M. O., Oladipo, O. O., Abayomi, O. A., & Adebayo, A. A. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148589 · Cited by 37
Viral Infections, Are They a Trigger and Risk Factor of Alzheimer’s Disease?
Rippee‐Brooks, M. D., Wu, W., Dong, J., Pappolla, M. A., Fang, X., & Bao, X. (2024) · Pathogens · doi:10.3390/pathogens13030240 · Cited by 32
“AD manifests as a progressive deterioration of cognitive functions, primarily encompassing the mutual characteristics of memory loss, impaired reasoning, and eventual debilitating disruptions to basic, everyday life [4].”
BackgroundALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M. (2025) · Brain Sciences · doi:10.3390/brainsci15020215 · Cited by 35
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Investigating the effects of Ginkgo biloba leaf extract on cognitive function in Alzheimer's disease
Zhu, C., Liu, J., Lin, J., Xu, J., & Yu, E. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14914 · Cited by 31
“13 The mechanism of action of GBE may involve modulation of both central and peripheral immune cells, manifesting as direct inhibition of central nervous system inflammation and regulation of peripheral immune cell activity. of GBE and existing AD drugs is also an important direction for future…”
BackgroundCui, D., Liu, H., Cao, L., Du, X., Liu, D., Liu, Z.-P., Wang, T., Yang, H., Zheng, X., Xie, Z., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05852-x · Cited by 33
“While certain meth-ods exist to ameliorate symptoms, a definite cure remains elusive [3, 4].”
Alzheimer's disease prediction using 3D-CNNs: Intelligent processing of neuroimaging data
Rahman, A. U., Ali, S., Saqia, B., Halim, Z., Al‐Khasawneh, M. A., AlHammadi, D. A., Khan, M. Z., Ullah, I., & Alharbi, M. (2025) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2025.100265 · Cited by 32
Debnath, I., Ghosh, S., Jha, S. K., Bhunia, S., Nayak, A., Basak, S., Nandi, S., & Bhattacharjee, S. (2025) · BIO Integration · doi:10.15212/bioi-2025-0073 · Cited by 35
“Memantine, which is an antagonist of NMDA receptors, is used experimentally to block glutamate receptors and protect against excitotoxic damage [102].”
Liu, Z., Kumar, M., & Kabra, A. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702071 · Cited by 32
“, loss of awareness, learning capacity, memory, judgment, reasoning, orientation, vocabulary) and has multifactorial pathogenesis involving oxidative stress, inflammation, cholinergic deficit, and neurotransmitters and hormonal imbalance [1].”
BackgroundResultLiang, Y.-J., Su, Q., Sheng, Z., Weng, Q., Niu, Y., Zhou, H., & Liu, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.830824 · Cited by 34
Liu, S., Chen, J., Zheng, W., Cui, J., & Wang, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.872530 · Cited by 33
“Its incidence is rising as the population ages and there are approximately 50 million people suffering from AD worldwide at present, which imposes a heavy burden on the society (Nichols et al., 2019; Breijyeh and Karaman, 2020).”
BackgroundDYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease
de Souza, M. M., Cenci, A. R., Teixeira, K. F., Machado, V., Schülerb, M. C. G. M., Gonçalves, A. E., Dalmagro, A. P., Cazarin, C. A., Ferreira, L. L. G., de Oliveira, A. S., et al. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220620162018 · Cited by 31
Li, W., Sun, L., Yue, L., & Xiao, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1120495 · Cited by 34
Psychobiotics for Mitigation of Neuro‐Degenerative Diseases: Recent Advancements
Dhyani, P., Goyal, C., Dhull, S. B., Chauhan, A. K., Saharan, B. S., Harshita, Duhan, J. S., & Gökşen, G. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300461 · Cited by 33
Astrocytes and microglia in the coordination of CNS development and homeostasis
Lopez‐Ortiz, A. O., & Eyo, U. B. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16006 · Cited by 51
Etekochay, M. O., Amaravadhi, A. R., González, G. V., Atanasov, A. G., Matin, M., Mofatteh, M., Steinbusch, H. W. M., Tesfaye, T., & Praticò, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231135 · Cited by 34
“Neuroimaging techniques have emerged as potent tools for investigating the underlying pathological mechanisms of AD and have contributed substantially into our understanding of the disease progression onset and progression [1, 19].”
The effect of CX3CL1/ CX3CR1 signal axis on microglia in central nervous system diseases
Zhao, J., Li, Q., Ouyang, X., Wang, F., Li, Q., Xu, Z., Ji, D., Wu, Q., Zhang, J., Lu, C., et al. (2023) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2023.100042 · Cited by 29
Qu, X., Zhang, L., & Wang, L. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c06238 · Cited by 36
Yang, X., Zhou, P., Zhao, Z., Li, J., Fan, Z., Li, X., Cui, Z., & Fu, A. (2023) · Antioxidants · doi:10.3390/antiox12112006 · Cited by 33
“In recent years, many potential reagents to improve AD symptoms have been studied, but about 99.6% of them fail in clinical trials [6–10].”
InfluentialThe Role of Atypical Chemokine Receptors in Neuroinflammation and Neurodegenerative Disorders
Lindsay, H. G., Hendrix, C. J., Murcia, J. D. G., Haynie, C., & Weber, K. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216493 · Cited by 30
“These plaques and tangles are neurotoxic leading to neuronal cell death and neurodegeneration [53].”
BackgroundNaik, B., Sasikumar, J., & Das, S. P. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04270-w · Cited by 33
“AD is characterized by the accumulation of insoluble amyloid beta (Aβ) forms in extracellular plaques and within the walls of cerebral arteries [67].”
Poblano, J., Castillo‐Tobías, I., Berlanga, L., Tamayo‐Ordoñez, M. C., Rodríguez‐Salazar, M. D. C., Silva‐Belmares, S. Y., Aguayo‐Morales, H., & Cobos-Puc, L. E. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14055 · Cited by 32
“2,5,6 Notably, while APOE alleles are the major genetic risk factor for late-onset Alzheimer ’ s disease (LOAD), mutations in genes such as PSEN and APP are associated with hereditary and early-onset (EOAD) forms of the disease, 6 underscoring the complex genetic nature of this pathology.”
Naik, R. A., Mir, M. N., Malik, I. A., Bhardwaj, R., Alshabrmi, F. M., Mahmoud, M. A., Alhomrani, M., Alamri, A. S., Alsanie, W. F., Hjazi, A. M., et al. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25551 · Cited by 35
Protein aggregation in neurodegenerative diseases
Wang, J., Dai, L., & Zhang, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003802 · Cited by 31
Induction of Brain Insulin Resistance and Alzheimer’s Molecular Changes by Western Diet
Mietelska‐Porowska, A., Domańska, J. M., Want, A., Więckowska‐Gacek, A., Chutorański, D., Koperski, M., & Wojda, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094744 · Cited by 30
“phosphorylated, aggregated tau protein (p-Tau) [2].”
BackgroundShared pathophysiology: Understanding stroke and Alzheimer’s disease
Sriram, S., Mehkri, Y., Quintin, S. S., & Lucke-Wold, B. P. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107306 · Cited by 29
A Dichotomous Role for FABP7 in Sleep and Alzheimer’s Disease Pathogenesis: A Hypothesis
Needham, H., Torpey, G., Flores, C. C., Davis, C. J., Vanderheyden, W. M., & Gerstner, J. R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.798994 · Cited by 29
Rejuvenation: Turning Back Time by Enhancing CISD2
Yeh, C., Shen, Z., Lin, C.-C., Lu, C.-K., & Tsai, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214014 · Cited by 30
“Alzheimer’s disease, or AD, which is characterized by loss of memory and deterioration in cognitive function, constitutes about two-thirds of cases of dementia among older adults [51].”
BackgroundViruses and amyloids - a vicious liaison
Hammarström, P., & Nyström, S. (2023) · Prion · doi:10.1080/19336896.2023.2194212 · Cited by 31
“…for many human amyloidogenic proteins, e.g . the difference between Aβ1–40 and Aβ1–42 where the 42 amino acid long peptide is much more amyloidogenic than the 40 amino acid long alloform and an increase of Aβ1–42/Aβ1–40 ratio is connected with increased risk for Alzheimer’s disease [83].”
Ganesh, G. S., Konduri, P., Kolusu, A. S., Namburi, S. V., Chunduru, B. T. C., Nemmani, K. V. S., & Samudrala, P. K. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00320 · Cited by 31
Alzheimer’s Disease Biomarker Detection Using Field Effect Transistor-Based Biosensor
Le, P. G., Choi, S. H., & Cho, S. (2023) · Biosensors · doi:10.3390/bios13110987 · Cited by 29
“Alzheimer’s disease (AD) is associated with neurodegeneration and causes many symptoms in the aging brain, including cognitive impairment [1].”
BackgroundSingh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03475-z · Cited by 28
“Synaptic dysfunction interacts with other core pathophysiology events of AD, such as the amyloid-β cascade, tau pathology, and neuroinflammation, eventually progressing to irreversible neurodegeneration and atrophy [72, 73].”
BackgroundA comprehensive multi-omics analysis reveals unique signatures to predict Alzheimer’s disease
Vacher, M. A., Cánovas, R., Laws, S. M., & Doecke, J. D. (2024) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2024.1390607 · Cited by 30
“The aetiology of AD is multifactorial, involving a combination of genetic, environmental, and epigenetic factors (Breijyeh and Karaman, 2020).”
BackgroundChakraborty, S., Karmakar, V., Chatterjee, K., Chatterjee, A., Dwivedi, M., & Gorain, B. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138336 · Cited by 30
Zulhafiz, N. A., Teoh, T.-C., Chin, A., & Chang, S. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108604 · Cited by 31
Hybrid Reptile-Snake Optimizer Based Channel Selection for Enhancing Alzheimer’s Disease Detection
Puri, D., Kachare, P. H., Khare, S. K., Al–Shourbaji, I., Jabbari, A., & Alameen, A. A. M. (2025) · Journal of Bionic Engineering · doi:10.1007/s42235-024-00636-x · Cited by 28
“The neuro-imaging techniques are also used for AD detection [2 ].”
Ha, Y., Jo, H.-S., Kwon, T. W., Jeon, S. H., Moon, S., Jung, J. H., Kim, M. S., Nah, S.-Y., Lee, J. K., & Cho, I. (2025) · Journal of Ginseng Research · doi:10.1016/j.jgr.2025.02.002 · Cited by 29
“Moreover, several risk factors, including increasing age, genetic predispositions, head injuries, vascular diseases, infections, and environmental influences, contribute to its pathology [42].”
Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care
Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 33
Second Sphere Interactions in Amyloidogenic Diseases
Roy, M., Nath, A. K., Pal, I., & Dey, S. G. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00941 · Cited by 29
Assessment of risk factors in dogs with presumptive advanced canine cognitive dysfunction
MacQuiddy, B., Moreno, J. A., Kusick, B. R., & McGrath, S. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.958488 · Cited by 31
Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer’s disease
Neha, N., & Parvez, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101815 · Cited by 32
Exosomes: A missing link between chronic systemic inflammation and Alzheimer’s disease?
Ozansoy, M., Mikati, H., Velioğlu, H. A., & Yuluğ, B. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114161 · Cited by 30
Preventive and Therapeutic Effects of Punica granatum L. Polyphenols in Neurological Conditions
Aleksandrova, S., Alexova, R., Dragomanova, S., Kalfin, R. E., Nicoletti, F., Fagone, P., Petralia, M. C., Mangano, K., & Tancheva, L. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031856 · Cited by 30
Transcranial pulse stimulation in Alzheimer's disease
Chen, X., You, J., Ma, H., Zhou, M., & Huang, C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14372 · Cited by 33
“7 However, these pharmacotherapies are accompanied by adverse effects and have limited effectiveness.”
BackgroundAlzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
Nystuen, K., McNamee, S. M., Akula, M., Holton, K. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11010045 · Cited by 29
Zou, D., Huang, X., Lan, Y., Pan, M., Xie, J., Huang, Q., Zeng, J., Zou, C., Pei, Z., Zou, C., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107098 · Cited by 30
Effects of Ginger (Zingiber officinale) on the Hallmarks of Aging
Matin, M., Joshi, T., Wang, D., Tzvetkov, N. T., Matin, F. B., Wierzbicka, A., Jóźwik, A., Horbańczuk, J. O., & Atanasov, A. G. (2024) · Biomolecules · doi:10.3390/biom14080940 · Cited by 33
“Alzheimer’s disease is an example of a complex multifactorial disease associated with protein degradation and aggregation, the pathogenesis of which involves the intersection of many biochemical pathways, and the exact mechanisms triggering the disease are still being debated [84].”
BackgroundArfaei, R., Mikaeili, N., Daj, F., Boroumand, A., Kheyri, A., Yaraghi, P., Shirzad, Z., Keshavarz, M., Hassanshahi, G., Jafarzadeh, A., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112328 · Cited by 27
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.